€57,48 €47,50 IVA esclusa
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle elicited upon exposure to inhalation anesthetics and depolarizing muscle relaxants.
Working days 10
Specifiche
| Breeds | |
|---|---|
| Gene | |
| Organ | |
| specimen | Swab, Blood EDTA, Blood Heparin, Semen, Tissue |
| Mode of Inheritance | |
| Chromosome | |
| Also known as | |
| Year Published |
Informazioni generali
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle elicited upon exposure to inhalation anesthetics and depolarizing muscle relaxants. It is considered to be a clinical syndrome rather than a single disease because multiple environmental and genetic factors cause a complex of events. MH has also been reported in humans, pigs, cats and horses.
Caratteristiche cliniche
MH-susceptible (MHS) dogs show no clinical signs until exposed to inhalation anesthetics and depolarizing muscle relaxants. When exposed, MHS dogs show tachycardia, hyperthermia, elevated CO2 levels and eventually death if the used anesthetic is not discontinued.
Informazioni aggiuntive
Riferimenti
Pubmed ID: 11575546, 15474681
Omia ID: 621
Prodotti correlati
-
H903Osteochondromatosis
- American Staffordshire Terrier
- EXT2
- Sistema scheletrico
-
- Spanish Water Dog
- PDE6B
- Organi di senso
-
- Cairn Terrier, Norfolk Terrier
- TUBB1
- Cardiovascular system
-
- Pug
- MYH9
- Apparati multipli
